Business Insights

DaVita’s Q4 2025 results were solid, but FY2025 was a mixed year. Revenue improved, adjusted EPS rose, but treatment volumes stayed weak.

Fresenius Medical Care delivered strong Q4 2025 results and improved meaningfully in FY2025 versus FY2024. But with reimbursement tailwinds fading and new investments rising, 2026 looks like a transition year.

Explores the key lessons from Barnett Helzberg's journey, illustrating how he transformed Helzberg Diamonds into a retail giant that attracted the attention of Warren Buffett.

Fresenius Medical Care AG's share price has declined in Jan 2026, raising questions for long-term investors. This analysis reviews FMS’s fundamentals.

Evolution AB faced challenges in Q3 due to regulatory issues in Asia and cybersecurity concerns. However, its global growth, strong margins, and solid long-term fundamentals indicate a more resilient outlook than the current share price reflects.

Adyen’s share price fell on tariffs and FX headwinds, but its long-term fundamentals remain strong.